In Brief: Graham-Field/Everest & Jennings
This article was originally published in The Gray Sheet
Graham-Field/Everest & Jennings: Modify terms of merger agreement announced June 17 ("The Gray Sheet" June 24, p. 9). Under the revised agreement, stockholders of Everest and Jennings will receive one share of Graham-Field common stock in exchange for 2.857 shares of Everest & Jennings common stock; the $14.4 mil. in cash to be paid to holders of E&J common stock under the previous agreement has been eliminated. Including E&J outstanding shares, Graham-Field will issue approximately 2.5 mil. shares for the acquisition. The merger ratio is subject to adjustment so that the value of E&J common stock does not exceed $5.50 per share as of the closing date. The merger is expected to close in November...
You may also be interested in...
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.